Cannabinoid Research Initiative of Saskatchewan
TypeAffiliated organization of University of Saskatchewan
Location
ServicesAcademic and applied research Cannabinoids
Medical Marijuana
Cannabis
Cannabidiol
Websiteresearch-groups.usask.ca/cris/index.php

The Cannabinoid Research Initiative of Saskatchewan (CRIS) was founded in 2017 as an interdisciplinary research team of clinician researchers (medical and veterinary), basic scientists, and social scientists. CRIS aims to obtain scientific evidence about the application of Cannabinoids and Medical cannabis to humans and animals, for health, disease and disorders. The team was initially based at the University of Saskatchewan, in Saskatoon, Saskatchewan, Canada but includes researchers based at the University of Regina and University of Alberta. A strategic management executive committee coordinates activities and develops research opportunities. The sections of CRIS include: Analytical Evaluations, Human Clinical Studies, Biomedical studies, Veterinary Sciences, Knowledge Translation and Studies of Cannabinoids and Society. CRIS members participate in the Canadian Consortium for the Investigation of Cannabinoids,[1] and the International Cannabinoid Research Society.[2]

The CARE-E clinical trial of a cannabis oil with high cannabidiol content with pediatric patients with refractory epilepsy was a key factor in initiating the research initiative. The CARE-E trial is a multi-center phase one trial that currently has open enrollment in five Canadian cities.[3] The CARE-E trial received extensive media coverage when it was launched. [4] [5] The therapeutic effect of pure cannabidiol (Epidiolex GW Pharmaceuticals) on Dravet Syndrome was recently reported in the New England Journal of Medicine [6] [7]

The CRIS group has expanded to biomedical science studies of the pharmacology of cannabinoids and synthetic cannabinoids. [8]

Laboratories

  • Drug Discovery Research Group -
(i) Determinants of neonatal exposure risk when breastfeeding mothers require medications.
(ii) Research into the health benefits of flaxseed lignans and their underlying mechanism(s) of action.[9][10]
  • Multiple Sclerosis Research - (i) Epidemiology and pharmacoepidemiology of MS.[11]
  • Clinical trials
(i) Clinical trials looking at cannabis in pediatric neurological disease.
(ii) Neuro-degenerative and neuro-metabolic disorders of childhood[12]
  • Type 1 cannabinoid receptor (CB1R) Pharmacology of the endocannabinoid system and the type 1 cannabinoid receptor (CB1R).[13]
  • Microbiome studies Project under development by the Links Lab [14]
  • Knowledge Translation Medication adherence, patient education and interprofessional education.[15]
  • Chronic Disease studies Use of interdisciplinary teams in chronic disease management, focusing on delivering diabetes care to immigrant and Aboriginal populations.[16]

See also

References

  1. ↑ "The Canadian Consortium for the Investigation of Cannabinoids". ccic.net. Retrieved 2017-12-27.
  2. ↑ "The International Cannabinoid Research Society". icrs.co. Retrieved 2017-12-27.
  3. ↑ "Cannabidiol in Children With Refractory Epileptic Encephalopathy - Full Text View – NCT03024827". ClinicalTrials.gov. Retrieved 2017-12-27.
  4. ↑ "Researchers studying usage, safety of cannabis oil for children with epilepsy - Saskatchewan - CBC News". cbc.ca. Retrieved 2017-12-27.
  5. ↑ "U of S study looks at using cannabis oil to treat children with epilepsy - Saskatoon". Globalnews.ca. Retrieved 2017-12-27.
  6. ↑ Devinsky, O.; Cross, J. H.; Laux, L.; Marsh, E.; Miller, I.; Nabbout, R.; Scheffer, I. E.; Thiele, E. A.; Wright, S.; Cannabidiol in Dravet Syndrome Study Group (2017). "Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome — NEJM" (PDF). The New England Journal of Medicine. 376 (21): 2011–2020. doi:10.1056/NEJMoa1611618. hdl:20.500.11820/2ed5e0db-7de9-4411-93d7-3a5c388006b9. PMID 28538134. S2CID 86481485.
  7. ↑ Berkovic, S. F. (2017). "Cannabinoids for Epilepsy — Real Data, at Last — NEJM". The New England Journal of Medicine. 376 (21): 2075–2076. doi:10.1056/NEJMe1702205. PMID 28538129.
  8. ↑ Bagher, AM; Laprairie, RB; Toguri, JT; Kelly, MEM; Denovan-Wright, EM (2017). "Bidirectional allosteric interactions between cannabinoid receptor 1 (CB1) and dopamine receptor 2 long (D2L) heterotetramers". Eur J Pharmacol. 813: 66–83. doi:10.1016/j.ejphar.2017.07.034. PMID 28734930. S2CID 25878852.
  9. ↑ "Discovery Research Group". usask.ca. Retrieved 2017-12-27.
  10. ↑ "Jane Alcorn - College of Pharmacy and Nutrition - University of Saskatchewan". pharmacy-nutrition.usask.ca. Retrieved 2017-12-27.
  11. ↑ "Charity Evans - College of Pharmacy and Nutrition - University of Saskatchewan". pharmacy-nutrition.usask.ca. Retrieved 2017-12-27.
  12. ↑ "Richard Huntsman - College of Medicine - University of Saskatchewan". medicine.usask.ca. Retrieved 2017-12-27.
  13. ↑ "Robert Laprairie - College of Pharmacy and Nutrition - University of Saskatchewan". pharmacy-nutrition.usask.ca. Retrieved 2017-12-27.
  14. ↑ "Lab Website for Dr. Matthew Links". coadunate.net. Retrieved 2017-12-27.
  15. ↑ "Holly Mansell - College of Pharmacy and Nutrition - University of Saskatchewan". pharmacy-nutrition.usask.ca. Retrieved 2017-12-27.
  16. ↑ "Kerry Mansell - College of Pharmacy and Nutrition - University of Saskatchewan". pharmacy-nutrition.usask.ca. Retrieved 2017-12-27.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.